NCT01827397View on ClinicalTrials.gov

Safety & Immunogenicity of Immunisations With EN41-UGR7C HIV Vaccine

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

February 28, 2014

Conditions

- HIV

Interventions

BIOLOGICAL

EN41-UGR7C HIV vaccine

BIOLOGICAL

NaCl

Trial Locations (1)

NW3 2QG

Royal Free Hospital; Royal Free London NHS Foundation Trust Pond Street, London

Sponsors

Lead Sponsor

PX'Therapeutics

All Listed Sponsors

collaborator

European Commission

OTHER

lead

PX'Therapeutics

INDUSTRY